Novel biologic agents (TNFa blockers) used in the treatment of many of these conditions are known to adversely affect the patient's ability to fight infection and their use has been identified as a risk factor for PJI following total joint arthroplasty [38, 39]. The gene discussed is TNF; the disease is infection.